Articles by tag: imp761

LAG-3 agonist IMP761: first clinical success in autoimmune diseases

LAG-3 agonist IMP761 has shown clinical efficacy in suppressing T-cells for the first time. Learn about the revolution in treating autoimmune diseases without side effects. Read more.

IMP761 — first LAG-3 agonist passes Phase I in autoimmune diseases

Analysis of IMP761 data from Immutep at EULAR 2026: a new class of drugs for treating rheumatoid arthritis without total immunosuppression. Safety, mechanism, and prospects. Read more.